O Balão Intra-Gástrico no Tratamento da Obesidade: Avaliação da Sua Eficácia, Segurança e Tolerabilidade

M. Bispo¹, M. J. Ferreira Da Silva¹, T. Bana¹, I. Seves¹, G. Couto¹, P. Peixe¹, S. Duarte², C. Gouveia², L. Matos¹

 

 

Resumo

Introdução:A OMS definiu como objectivo principal do tratamento da obesidade, uma redução de peso de 10 a 15%, para diminuição do risco cardiovascular global e comorbilidades associadas.

Objectivos: Caracterizar e analisar a eficácia a curto e longo-prazo, segurança e tolerabilidade do balão intra-gástrico (BIG) no tratamento da obesidade.

Métodos: Estudo retrospectivo do tratamento com 210 BIGs, em 194 doentes, entre Outubro/2000 e Junho/2007. A maioria dos doentes apresentava obesidade mórbida (IMC

médio 47,8Kg/m2), com comorbilidades significativas. O tempo médio de permanência do BIG foi 7 meses.

Resultados: No final do tratamento, constatou-se uma redução ponderal média de 12,9%. Obteve-se “sucesso clínico” (redução ponderal ≥10%), na maioria dos casos (60,5%). Em 2 grupos de 52 doentes hipertensos e 30 diabéticos, registou-se melhoria destas comorbilidades durante o tratamento em 61,5% e 66,7%, respectivamente. Não se registaram complicações significativas associadas ao BIG. Analisando a longo-prazo (12 meses após remoção) um coorte de 91 doentes, a redução média de peso foi 5,6%, sendo significativamente superior (>2 vezes) nos doentes com mais de 50 anos.

Conclusões: O BIG é seguro e apresenta uma taxa de sucesso clínico satisfatória a curto-prazo, com melhoria das principais comorbilidades. A longo-prazo, foi mais eficaz nas faixas etárias mais avançadas.

 

 

Summary

Background: The main goal proposed by the WHO in obesity treatment, in order to reduce cardiovascular risk and related comorbidities, is a 10-15% weight-loss.

Aims: To characterize and analyze short and long-term efficacy, safety and tolerability of BioEnterics® Intragastric Balloon (BIB) in obesity treatment.

Patients and Methods: Retrospective study on data of 210 BIB procedures in 194 patients, between October/2000 and June/2007. Most patients presented with morbid obesity (mean BMI 47,8Kg/m2) and heavy comorbidities. Average BIB stay was 7 months.

Results: On BIB removal, the mean weight-loss was 12,9%. “Clinical success” (weight-loss ≥10%) was achieved in most cases (60,5%). In two groups of 52 hypertensive and 30 diabetic patients, there was a 61,5% and 66,7% improvement in these comorbidities, respectively, during treatment. There were no major complications associated to BIB. On longterm analysis (12 month after BIB removal) of a 91 patients cohort, global weight-loss was 5,6%, being significantly higher (>2-fold) in patients over 50 years-old.

Conclusions: BIB is safe, shows satisfactory short-term cli nical success rate, with improvement in co-morbidities. On long-term, higher efficacy was seen in older patients.

 

 

Texto Completo disponível apenas em PDF

Full text only available in PDF format

 

 

Bibliografia

 

1. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity. WHO Technical Support Series 1998; Geneva. 1-276.        [ Links ]

2. National Institutes of Health, National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults - the evidence report. Obes Res 1998; 6 (Suppl 2):51S-209S.

3. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity. Gastroenterology 2002; 123 (3): 882-932.

4. Caterson ID, Gill TP. (2002). Obesity: epidemiology and possible prevention. Best Pract Res Clin Endocrinol Metab 2006.16(4):595-610.

5. World Health Organization. The challenge of obesity in the WHO European Region. Fact sheet EURO Set 2005. Copenhagen, Bucharest.

6. Kopelman PG. Obesity as a medical problem. Nature 2000; 404:635-643.

7. Carmo I, Santos O, Camolas J, Vieira J, Carreira M, Medina L, Reis L, Galvão-Teles A. Prevalence of obesity in Portugal. Obes Rev 2006. 7:233-237.

8. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Health CW. Bodymass índex and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097-1105.

9. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12:1106-1110.

10. Bellentani S, Saccocio G, Masutti F. Prevalence of and risk factors for hepatic steatosis in Northen Italy. Ann Intern Med 2000;132:112-117.

11. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45(4): 600-6.

12. Ratziu V, Giral P, Charlotte F. Liver fibrosis in overweight patients. Gastroenterology 2000; 118: 1117-1123.

13. Fontaine KR, Cheskin LJ, Barofsky I. Health-realted quality of life in obese persons seeking treatment. J Fam Pract 1996; 43: 265-270.

14. Glenny AM, O’Meara S, Melville A, Sheldon TA, Wilson C. The treatment and prevention of obesity: a systematic review of the literature. Int J Obes Relat Metab Disord 1997; 21: 715-37.

15. Lee K, Lee MJ, Birmingham L. Obesity diagnosis and treatment algorithm. BC Medical Journal 2002; 44 (3): 126-130.

16. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000; 1 (2), 113–119.

17. Yanovski S. Z. Pharmacotherapy for Obesity – Promise and Uncertainty. N Engl J Med 2005; 353: 2187-2189.

18. NIH conference: gastrointestinal surgery for severe obesity: consensus development conference panel. Ann Intern Med 1991; 115: 956-961.

19. Sanyal AJ, Sugerman HJ, Kellum JM, Engle KM, Wolfe L. Stomal  complications of gastric bypass: incidence and outcome of therapy.Am J Gastroenterol 1992; 87: 1165-1169.

20. DeMaria EJ, Sugerman HJ, Kellum JM. High failure rate following laparoscopic adjustable silicone gastric banding for treatment of morbid obesity. Ann Surg 2001: 233: 809-818.

21. Hauri P, Steffen R, Ricklin T, Riedtmann HJ, Sendi P, Horber FF. Treatment of morbid obesity with the Swedish adjustable gastric band: complication rate during a 12-month follow-up period. Surgery 2000; 127: 484-488.

22. Gustavsson S. Laparoscopic adjustable gastric banding – a caution. Surgery 2000; 127:489-490.

23. Schapiro M, Benjamin S, Blackburn G, Frank B, Heber D, Ko zarek R, et al. Obesity and the gastric balloon: a comprehensive workshop. Tarpon Springs, Florida. Gastrointest Endosc 1987; 33: 323-7.

24. Mathus-Vliegen EMH, Tytgat GNJ. Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span. Br J Surg 1990; 77: 76-9.

25. Genco A, Bruni T, Doldi SB, Forestieri P, Marino M, Busetto L, et al. BioEnterics Intragastric Balloon: the italian experience with 2.515 patients. Obes Surg 2005; 15(8):1161-4.

26. Doldi SB, Micheletto G, Perrini MN, Rapetti R. Intragastric balloon: another option for treatment of obesity and morbid obesity. Hepatogastroenterology 2004; 51(55): 294-7.

27. Totté E, Hendrickx L, Pauwels M. Weight reduction by means of intragastric device: experience with the BioEnterics Intragastric Bal loon. Obes Surg 2001; 11: 330-333.

28. Evans JD, Scott MH. Intragastric balloon in the treatment of pa tients with morbid obesity. Br J Surg. 2001. 88(9):1245-8.

29. Mathus-Vliegen EMH, Tytgat GNJ, Veldhuyzen-Offermans EAML. Intragastric ballon in the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover evaluation of 500-milliliter balloon. Gastroenterology 1999; 99: 362-9.

30. Herve J, Wahlen CH, Shaeken A. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg 2005; 15(6):864-70.

31. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005. 61(1):19-27.

32. Angrisani L, Lorenzo M, Borrelli V, Giuffré M, Fonderico C, Capece G. Is bariatric surgery necessary after intragastric balloon treatment? Obes Surg 2006; 16(9):1135-7.

33. Wadden TA, Foster GD. Behavioral treatment of obesity. Med Clin North Am 2000; 84:441-61.

34. Sjostrom L, Rissanen A, Andersen T. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-172.

35. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:379-415.

36. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people. The Trials of Hypertension Prevention, phase II. Arch Intern Med 1997;157:657-667.

37. Kuhlmann HW, Falcone RA, Wolf AM. Cost-effective bariatric surgery in Germany today. Obes Surg 2000; 10:540-546.

38. Wing RR, Koeske R, Epstein LH, Nowalk MP, Gooding W, Becker D. Long-term effects of modest weight lost in type II diabetic patients. Arch Intern Med 1997;147:1749-1753.

39. Mathus-Vliegen EMH, Tytgat GNJ, Veldhuyzen-Offermans EA LM. Intragastric ballon in the treatment of super-morbid obesity. Gastroenterology 1990;99:362-369.

40. Narbro K, Agren G, Jonsson E. Sick leave and disability pension before and after treatment for obesity: a report from the Swedish Obese Subjects (SOS) study. Int J Obes Relat Metab Disord 1999;23:619-624.

 

 

(1) Serviço de Gastrenterologia.

(2) Serviço de Endocrinologia.

Centro Hospitalar de Lisboa Ocidental, E.P.E. – Hospital de Egas Moniz, Lisboa, Portugal.

 

Correspondência:

Miguel Bispo

Serviço de Gastrenterologia

Centro Hospitalar de Lisboa Ocidental, E.P.E. – Hospital de Egas Moniz

Calçada do Moinho de Vento, nº 18, 3º A

1150-236 Lisboa

Tel.: (+351) 919 002 599

e-mail: bispomiguel@hotmail.com

 

Recebido para publicação: 10/12/2007

Aceite para publicação: 07/04/2008